Cardiovascular risk assessment by physicians and lipid-lowering therapy prescribing in high- and very high-risk patients: Results from the multinational observational santorini study

Ray, Kausik K.; Haq, Inaam; Bilitou, Aikaterini; Manu, Marius Constantin; Burden, A; Catapano, A.L.

doi:10.1016/j.atherosclerosis.2022.06.955

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we utilized all available information in the EHR to calculate CV risk, which could potentially identify high and very high CV risk patients not evident to the physicians. This difference in risk assessment methodology may account for the slightly better results in LDL‐C attainment observed in the SANTORINI study compared to our study 26,27 …”

Section: Discussionmentioning

confidence: 52%

“…This difference in risk assessment methodology may account for the slightly better results in LDL‐C attainment observed in the SANTORINI study compared to our study. 26 , 27 …”

Section: Discussionmentioning

confidence: 99%

“…This difference in risk assessment methodology may account for the slightly better results in LDL-C attainment observed in the SANTORINI study compared to our study. 26,27 The earlier DYSIS and DYSIS II cohorts have revealed that a large portion of patients with very high CV risk fail to reach their LDL-C goals, even when treated with LLT. In particular, only 21.7% of very high-risk patients reached their LDL-C goals in the DYSIS study, and in the DYSIS II study with patients with chronic CAD, only 29.6% of those on LLT and 8.3% of those untreated achieved LDL-C levels <70 mg/dL.…”

Section: Intervention To Reduce Events V Of Esc-eurobservational Rese...mentioning

confidence: 99%

See 2 more Smart Citations

Characterization and LDL‐C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT‐DYS study

Gavina,

Seabra‐Carvalho,

Aguiar

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

AimThis study aims to characterize sociodemographic and clinical characteristics, use of lipid‐lowering therapies (LLTs), and low‐density lipoprotein cholesterol (LDL‐C) control in a population with increased cardiovascular (CV) risk.MethodsA cross‐sectional observational study that uses electronic health records of patients from one hospital and across 14 primary care health centers in the North of Portugal, spanning from 2000 to 2020 (index date). Patients presented at least (i) 1 year of clinical data before inclusion, (ii) one primary care appointment 3 years before the index date, and (iii) sufficient data for CV risk classification. Patients were divided into three cohorts: high CV risk; atherosclerotic cardiovascular disease (ASCVD) risk equivalents without established ASCVD; evidence of ASCVD. CV risk and LDL‐C control were defined by the 2019 and 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidemia guidelines.ResultsA total of 51 609 patients were included, with 23 457 patients classified as high CV risk, 19 864 with ASCVD equivalents, and 8288 with evidence of ASCVD. LDL‐C control with 2016 ESC/EAS guidelines was 32%, 10%, and 18% for each group, respectively. Considering the ESC/EAS 2019 guidelines control level was even lower: 7%, 3%, and 7% for the same cohorts, respectively. Patients without any LLT prescribed ranged from 37% in the high CV risk group to 15% in patients with evidence of ASCVD.ConclusionWe found that LDL‐C control was very low in patients at higher risk of CV events. An alarming gap between guidelines on dyslipidemia management and clinical implementation persists, even in those at very high risk or with established ASCVD.

show abstract

Section: Discussionmentioning

confidence: 52%

“…This difference in risk assessment methodology may account for the slightly better results in LDL‐C attainment observed in the SANTORINI study compared to our study. 26 , 27 …”

Section: Discussionmentioning

confidence: 99%

Section: Intervention To Reduce Events V Of Esc-eurobservational Rese...mentioning

confidence: 99%

See 1 more Smart Citation

Characterization and LDL‐C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT‐DYS study

Gavina,

Seabra‐Carvalho,

Aguiar

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

Lipidmanagement bei Typ-2-Diabetes mellitus – Strategien zur Risikoreduktion

Brandts

2024

Aktuelle Kardiologie

View full text Add to dashboard Cite

ZusammenfassungPatienten mit Typ-2-Diabetes (T2D) weisen ein doppelt so hohes Risiko für kardiovaskuläre Ereignisse auf wie die Allgemeinbevölkerung, ein Risiko, das teilweise durch Senkung von Apolipoprotein-B100-haltigen Lipoproteinen reduziert werden könnte. Allerdings erreichen wenige die empfohlenen LDL-Cholesterin-Zielwerte aufgrund hoher Ausgangswerte, Therapieunverträglichkeiten und ärztlicher Risikounterschätzung. Der SCORE2-Diabetes bietet eine präzise Risikobewertung, indem er konventionelle und diabetesspezifische Faktoren einbezieht. Behandlungsbasis bilden weiterhin Statine, doch oft sind Kombinationstherapien mit Ezetimib oder Bempedoinsäure nötig. PCSK9-Inhibitoren sind eine effektive Option für Hochrisikopatienten. Durch den strategischen Einsatz dieser Therapieansätze kann das Management von Lipiden bei T2D-Patienten erheblich verbessert und damit das Risiko für kardiovaskuläre Ereignisse reduziert werden.

show abstract

Lipidmanagement bei Typ-2-Diabetes mellitus

Brandts

2024

Diabetes aktuell

View full text Add to dashboard Cite

ZUSAMMENFASSUNGPatienten mit Typ-2-Diabetes (T2 D) weisen ein doppelt so hohes Risiko für kardiovaskuläre Ereignisse auf wie die Allgemeinbevölkerung, ein Risiko, das teilweise durch Senkung von Apolipoprotein-B100-haltigen Lipoproteinen reduziert werden könnte. Allerdings erreichen wenige die empfohlenen LDL-Cholesterin-Zielwerte aufgrund hoher Ausgangswerte, Therapieunverträglichkeiten und ärztlicher Risikounterschätzung. Der SCORE2-Diabetes bietet eine präzise Risikobewertung, indem er konventionelle und diabetesspezifische Faktoren einbezieht. Behandlungsbasis bilden weiterhin Statine, doch oft sind Kombinationstherapien mit Ezetimib oder Bempedoinsäure nötig. PCSK9-Inhibitoren sind eine effektive Option für Hochrisikopatienten. Durch den strategischen Einsatz dieser Therapieansätze kann das Management von Lipiden bei T2D-Patienten erheblich verbessert und damit das Risiko für kardiovaskuläre Ereignisse reduziert werden.

show abstract

Cardiovascular risk assessment by physicians and lipid-lowering therapy prescribing in high- and very high-risk patients: Results from the multinational observational santorini study

Cited by 3 publications

References 0 publications

Characterization and LDL‐C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT‐DYS study

Characterization and LDL‐C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT‐DYS study

Lipidmanagement bei Typ-2-Diabetes mellitus – Strategien zur Risikoreduktion

Lipidmanagement bei Typ-2-Diabetes mellitus

Contact Info

Product

Resources

About